Literature DB >> 16136355

Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis.

Martin Raida1, Joachim H Clement, Russell D Leek, Kurosh Ameri, Roy Bicknell, Dietger Niederwieser, Adrian L Harris.   

Abstract

PURPOSE: Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta family and play an important role in the regulation of embryonic vasculogenesis but their role in postnatal angiogenesis remains to be clarified. In this study we investigated a possible role of BMP-2 in the promotion of tumor angiogenesis.
METHODS: We studied the effect of BMP-2 on human dermal microvascular endothelial cells (HDMECs) and examined a possible angiogenic activity of BMP-2 with the mouse sponge assay. The effect of BMP-2 overexpression on tumor vascularization was also analyzed in xenografts of human BMP-2 transfected MCF-7 breast cancer cells (MCF-7/BMP2) in mice.
RESULTS: BMP receptor activation selectively induced the phosphorylation of p38 mitogen-activated protein kinase (MAPK) in contrast to the ERK1/2 MAP kinases. In keeping with this finding, BMP-2 had no significant effect on endothelial cell proliferation but promoted HDMEC tube formation in the matrigel assay. The transcription factor inhibitor of differentiation 1 (Id1), which is known to play an important role in neovascularization of tumors, was confirmed as a BMP target in HDMECs. Immunohistochemical analysis of sponge sections revealed that BMP-2 induced vascularization and showed an additive enhancement of angiogenesis with VEGF. In the murine breast cancer xenograft model, human MCF-7 cells with stable overexpression of BMP-2 developed vascularized tumors while empty vector control MCF-7 cells failed to form tumors.
CONCLUSIONS: We conclude that activation of the BMP pathway by BMP-2 can promote vascularization and might be involved in tumor angiogenesis possibly by stimulating the Id1 and p38 MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136355     DOI: 10.1007/s00432-005-0024-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  46 in total

1.  Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.

Authors:  P Carmeliet; L Moons; A Luttun; V Vincenti; V Compernolle; M De Mol; Y Wu; F Bono; L Devy; H Beck; D Scholz; T Acker; T DiPalma; M Dewerchin; A Noel; I Stalmans; A Barra; S Blacher; T VandenDriessche; A Ponten; U Eriksson; K H Plate; J M Foidart; W Schaper; D S Charnock-Jones; D J Hicklin; J M Herbert; D Collen; M G Persico
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

2.  Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: importance of BMP2.

Authors:  S F Arnold; E Tims; B E Mcgrath
Journal:  Cytokine       Date:  1999-12       Impact factor: 3.861

3.  Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts.

Authors:  D Lyden; A Z Young; D Zagzag; W Yan; W Gerald; R O'Reilly; B L Bader; R O Hynes; Y Zhuang; K Manova; R Benezra
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

4.  Angiogenin activates Erk1/2 in human umbilical vein endothelial cells.

Authors:  S Liu; D Yu; Z P Xu; J F Riordan; G F Hu
Journal:  Biochem Biophys Res Commun       Date:  2001-09-14       Impact factor: 3.575

5.  Osteogenin and recombinant bone morphogenetic protein 2B are chemotactic for human monocytes and stimulate transforming growth factor beta 1 mRNA expression.

Authors:  N S Cunningham; V Paralkar; A H Reddi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

6.  Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells.

Authors:  Frédéric Pouliot; Alexandre Blais; Claude Labrie
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

7.  Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis.

Authors:  S B Fox; R D Leek; M P Weekes; R M Whitehouse; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-11       Impact factor: 7.996

8.  Differential expression and regulation of bone morphogenetic protein 7 in breast cancer.

Authors:  Manuela Schwalbe; Jörg Sänger; Ralf Eggers; Anke Naumann; Andreas Schmidt; Klaus Höffken; Joachim H Clement
Journal:  Int J Oncol       Date:  2003-07       Impact factor: 5.650

9.  Angiogenesis defects and mesenchymal apoptosis in mice lacking SMAD5.

Authors:  X Yang; L H Castilla; X Xu; C Li; J Gotay; M Weinstein; P P Liu; C X Deng
Journal:  Development       Date:  1999-04       Impact factor: 6.868

Review 10.  Bone morphogenetic proteins, genetics and the pathophysiology of primary pulmonary hypertension.

Authors:  M De Caestecker; B Meyrick
Journal:  Respir Res       Date:  2001-06-11
View more
  64 in total

1.  Bone morphogenetic protein 4 (BMP4) is required for migration and invasion of breast cancer.

Authors:  Dan Guo; Jiayi Huang; Jianping Gong
Journal:  Mol Cell Biochem       Date:  2011-12-14       Impact factor: 3.396

Review 2.  Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates.

Authors:  David M Wiley; Suk-Won Jin
Journal:  Semin Cell Dev Biol       Date:  2011-10-12       Impact factor: 7.727

3.  Improved growth factor directed vascularization into fibrin constructs through inclusion of additional extracellular molecules.

Authors:  J D Smith; M E Melhem; K T Magge; A S Waggoner; P G Campbell
Journal:  Microvasc Res       Date:  2007-01-16       Impact factor: 3.514

4.  The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation.

Authors:  Guangheng Li; Karin Corsi-Payne; Bo Zheng; Arvydas Usas; Hairong Peng; Johnny Huard
Journal:  Tissue Eng Part A       Date:  2009-08       Impact factor: 3.845

5.  Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

Authors:  Yanli Song; Laura Coleman; Jianru Shi; Hideyuki Beppu; Kaori Sato; Kenneth Walsh; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-13       Impact factor: 4.733

6.  WSS25 inhibits growth of xenografted hepatocellular cancer cells in nude mice by disrupting angiogenesis via blocking bone morphogenetic protein (BMP)/Smad/Id1 signaling.

Authors:  Hong Qiu; Bo Yang; Zhi-Chao Pei; Zhang Zhang; Kan Ding
Journal:  J Biol Chem       Date:  2010-08-02       Impact factor: 5.157

7.  Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Authors:  Mei-Yu Hsu; Sherry A Rovinsky; Chiou-Yan Lai; Shadi Qasem; Xiaoming Liu; Joan How; John F Engelhardt; George F Murphy
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

8.  Nuclear variants of bone morphogenetic proteins.

Authors:  Jenny E Felin; Jaime L Mayo; Trina J Loos; J Daniel Jensen; Daniel K Sperry; Stephanie L Gaufin; Christopher A Meinhart; Jennie B Moss; Laura C Bridgewater
Journal:  BMC Cell Biol       Date:  2010-03-15       Impact factor: 4.241

9.  Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway.

Authors:  Ying Zheng; Xuemei Wang; Haidong Wang; Wei Yan; Quan Zhang; Xin Chang
Journal:  Tumour Biol       Date:  2014-02-27

10.  Notochord-derived BMP antagonists inhibit endothelial cell generation and network formation.

Authors:  Michael Bressan; Patricia Davis; John Timmer; Doris Herzlinger; Takashi Mikawa
Journal:  Dev Biol       Date:  2008-11-12       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.